1. Home
  2. PHVS vs VVX Comparison

PHVS vs VVX Comparison

Compare PHVS & VVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHVS
  • VVX
  • Stock Information
  • Founded
  • PHVS 2015
  • VVX 2014
  • Country
  • PHVS Switzerland
  • VVX United States
  • Employees
  • PHVS N/A
  • VVX N/A
  • Industry
  • PHVS Biotechnology: Pharmaceutical Preparations
  • VVX Diversified Commercial Services
  • Sector
  • PHVS Health Care
  • VVX Consumer Discretionary
  • Exchange
  • PHVS Nasdaq
  • VVX Nasdaq
  • Market Cap
  • PHVS 1.6B
  • VVX 1.8B
  • IPO Year
  • PHVS 2021
  • VVX 2014
  • Fundamental
  • Price
  • PHVS $22.46
  • VVX $58.91
  • Analyst Decision
  • PHVS Buy
  • VVX Buy
  • Analyst Count
  • PHVS 6
  • VVX 10
  • Target Price
  • PHVS $36.50
  • VVX $62.60
  • AVG Volume (30 Days)
  • PHVS 217.3K
  • VVX 213.4K
  • Earning Date
  • PHVS 11-12-2025
  • VVX 11-03-2025
  • Dividend Yield
  • PHVS N/A
  • VVX N/A
  • EPS Growth
  • PHVS N/A
  • VVX N/A
  • EPS
  • PHVS N/A
  • VVX 2.19
  • Revenue
  • PHVS N/A
  • VVX $4,333,661,000.00
  • Revenue This Year
  • PHVS N/A
  • VVX $4.18
  • Revenue Next Year
  • PHVS N/A
  • VVX $5.49
  • P/E Ratio
  • PHVS N/A
  • VVX $26.69
  • Revenue Growth
  • PHVS N/A
  • VVX 5.07
  • 52 Week Low
  • PHVS $11.51
  • VVX $41.08
  • 52 Week High
  • PHVS $26.33
  • VVX $69.75
  • Technical
  • Relative Strength Index (RSI)
  • PHVS 47.79
  • VVX 52.75
  • Support Level
  • PHVS $21.99
  • VVX $58.51
  • Resistance Level
  • PHVS $23.64
  • VVX $61.90
  • Average True Range (ATR)
  • PHVS 1.28
  • VVX 2.05
  • MACD
  • PHVS -0.01
  • VVX -0.20
  • Stochastic Oscillator
  • PHVS 52.17
  • VVX 51.62

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

About VVX V2X Inc.

V2X Inc is a U.S.-based company that provides services to the U.S. government. It operates as one segment and offers facility and logistics services and information technology mission support and engineering and digital integration services. The information technology and network communications capabilities consist of communications systems operations and maintenance, management and service support, systems installation and activation, system-of-systems engineering and software development, and mission support for the department of defense. The facility and logistics service include airfield management, ammunition management, civil engineering, communications, emergency services, life support activities, public works, security, transportation operations, and others.

Share on Social Networks: